133 related articles for article (PubMed ID: 29553968)
61. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
62. Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
Osako T; Horii R; Matsuura M; Ogiya A; Domoto K; Miyagi Y; Takahashi S; Ito Y; Iwase T; Akiyama F
J Cancer Res Clin Oncol; 2010 Feb; 136(2):233-41. PubMed ID: 19685074
[TBL] [Abstract][Full Text] [Related]
63. Image Analysis of HER2 Immunohistochemical Staining of Surgical Breast Cancer Specimens.
Yim K; Park HS; Kim DM; Lee YS; Lee A
Yonsei Med J; 2019 Feb; 60(2):158-162. PubMed ID: 30666837
[TBL] [Abstract][Full Text] [Related]
64. HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern.
Perron M; Wen HY; Hanna MG; Brogi E; Ross DS
Arch Pathol Lab Med; 2021 Aug; 145(8):979-987. PubMed ID: 33212478
[TBL] [Abstract][Full Text] [Related]
65. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
66. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.
Yamamoto S; Ibusuki M; Yamamoto Y; Fu P; Fujiwara S; Murakami K; Iwase H
Breast Cancer; 2013 Jul; 20(3):262-70. PubMed ID: 22362219
[TBL] [Abstract][Full Text] [Related]
67. Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women.
Ma H; Lu Y; Marchbanks PA; Folger SG; Strom BL; McDonald JA; Simon MS; Weiss LK; Malone KE; Burkman RT; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
Breast Cancer Res; 2013; 15(5):R90. PubMed ID: 24070170
[TBL] [Abstract][Full Text] [Related]
68. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases.
Collins LC; Botero ML; Schnitt SJ
Am J Clin Pathol; 2005 Jan; 123(1):16-20. PubMed ID: 15762275
[TBL] [Abstract][Full Text] [Related]
69. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
70. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
71. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.
Shekhar MP; Kato I; Nangia-Makker P; Tait L
Oncotarget; 2013 Feb; 4(2):231-41. PubMed ID: 23548208
[TBL] [Abstract][Full Text] [Related]
72. Paraffin-embedded Tissue Fragment Suspension (PETFS): A Novel Method for Quality Control Preparation in Immunohistochemistry.
Ding W; Huang K; Lü B; Xu L; Liu J; Jiang C; Teng X; Ren X; Wang B
Appl Immunohistochem Mol Morphol; 2017; 25(10):746-753. PubMed ID: 27153444
[TBL] [Abstract][Full Text] [Related]
73. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
Bossuyt V; Fadare O; Martel M; Ocal IT; Burtness B; Moinfar F; Leibl S; Tavassoli FA
Int J Surg Pathol; 2005 Oct; 13(4):319-27. PubMed ID: 16273187
[TBL] [Abstract][Full Text] [Related]
74. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
Zhong F; Bi R; Yu B; Yang F; Yang W; Shui R
PLoS One; 2016; 11(2):e0150505. PubMed ID: 26928407
[TBL] [Abstract][Full Text] [Related]
75. Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies.
Hicks D; Dell'Orto P; Falzon M; Hoff KD; Levy YY; McMahon L; Miller K; Russo L; Viale G
Appl Immunohistochem Mol Morphol; 2017; 25(5):313-319. PubMed ID: 26657878
[TBL] [Abstract][Full Text] [Related]
76. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
[TBL] [Abstract][Full Text] [Related]
77. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
78. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
79. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections.
Atkins D; Reiffen KA; Tegtmeier CL; Winther H; Bonato MS; Störkel S
J Histochem Cytochem; 2004 Jul; 52(7):893-901. PubMed ID: 15208356
[TBL] [Abstract][Full Text] [Related]
80. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Robertson S; Rönnlund C; de Boniface J; Hartman J
Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
